|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-1-21
|
|
pubmed:abstractText |
Intervention studies have shown that angiotensin receptor blockers (ARB) may reduce the incidence of type 2 diabetes mellitus. It is currently unclear whether short-term therapy with ARBs affects metabolic parameters.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1742-1241
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
64
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
160-8
|
|
pubmed:meshHeading |
pubmed-meshheading:19929980-Adult,
pubmed-meshheading:19929980-Aged,
pubmed-meshheading:19929980-Analysis of Variance,
pubmed-meshheading:19929980-Antihypertensive Agents,
pubmed-meshheading:19929980-Biphenyl Compounds,
pubmed-meshheading:19929980-Diabetes Mellitus, Type 2,
pubmed-meshheading:19929980-Double-Blind Method,
pubmed-meshheading:19929980-Female,
pubmed-meshheading:19929980-Humans,
pubmed-meshheading:19929980-Hypertension,
pubmed-meshheading:19929980-Insulin Resistance,
pubmed-meshheading:19929980-Lipids,
pubmed-meshheading:19929980-Male,
pubmed-meshheading:19929980-Metabolic Syndrome X,
pubmed-meshheading:19929980-Middle Aged,
pubmed-meshheading:19929980-Risk Factors,
pubmed-meshheading:19929980-Tetrazoles,
pubmed-meshheading:19929980-Treatment Outcome,
pubmed-meshheading:19929980-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND).
|
|
pubmed:affiliation |
Medizinische Klinik II, Grosshadern, Klinikum der Universitaet, Munich, Germany. Klaus.Parhofer@med.unimuenchen.de
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
